MindWalk Holdings (HYFT) Revenue (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Revenue of $3.0 billion for Q2 2026, down 38.81% year-over-year from $4.9 billion in Q2 2025, and up 100093.2% quarter-over-quarter from $3.0 million in Q1 2026.
MindWalk Holdings (HYFT) Revenue (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Revenue for 7 consecutive years, with $3.0 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Revenue fell 38.81% year-over-year to $3.0 billion; the TTM figure through Apr 2026 stood at $6.0 billion (down 10.95% YoY), while the FY2026 annual figure was $11.3 million, up 48.78% from the prior year.
- Revenue rose to $3.0 billion in Q2 2026 per HYFT's latest filing, from $3.0 million in the prior quarter.
- Across five years, Revenue topped out at $4.9 billion in Q2 2025 and bottomed at -$5.7 million in Q2 2024.
- Historically, Revenue has averaged $707.1 million across 5 years, with a median of $4.0 million in 2022.
- Annual changes were most pronounced in 2022 — Revenue soared 106803022.75% — and 2024, when it slumped 238.12%.
- MindWalk Holdings' Revenue stood at $3.9 million in 2022, then rose by 16.21% to $4.5 million in 2023, then sank by 56.75% to $2.0 million in 2024, then soared by 151439.55% to $3.0 billion in 2025, then rose by 0.98% to $3.0 billion in 2026.
- Business Quant data shows HYFT's Revenue at $3.0 billion in Q2 2026, $3.0 million in Q1 2026, and $3.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 3.00 Bn |
| Jan 31, 2026 | 3.00 Mn |
| Oct 31, 2025 | 2.97 Bn |
| Jul 31, 2025 | 2.30 Mn |
| Apr 30, 2025 | 4.91 Bn |
| Jan 31, 2025 | 1.92 Mn |
| Oct 31, 2024 | 1.96 Mn |
| Jul 31, 2024 | 1.81 Bn |
| Apr 30, 2024 | -5.74 Mn |
| Jan 31, 2024 | 4.60 Mn |
| Oct 31, 2023 | 4.54 Mn |
| Jul 31, 2023 | 4.26 Mn |
| Apr 30, 2023 | 4.15 Mn |
| Jan 31, 2023 | 3.83 Mn |
| Oct 31, 2022 | 3.90 Mn |
| Jul 31, 2022 | 3.65 Mn |
| Apr 30, 2022 | 4.14 Mn |
| Jan 31, 2022 | 3.80 Mn |
| Oct 31, 2021 | 3,782.31 |
| Jul 31, 2021 | 3,734.55 |